Clearcam Inc.'s Kelling device has an improved view of the market thanks to the closing of a $2.6 million series 2 seed financing round, led by investor and entrepreneur Frank Barbella, CEO of Solv Risk Solutions.
LONDON – Antifungal specialist F2G Ltd. has closed a $60.8 million round, providing the means to complete phase III development of the lead product olorofim, a treatment for life-threatening invasive infections, and to scale up in preparation for commercialization.
HONG KONG – Venture capital investment into most sectors in China has generally plunged throughout the COVID-19 pandemic but biotechnology has been a noticeable exception. China’s biotech industry has continued to attract investors, not only because of its importance in dealing with the pandemic but also as a result of increased maturity and a growing list of government incentives.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Anheart, Curevac, Myovant Sciences, Sumitomo Dainippon, Taiwan Ministry of Health and Welfare, Tiziana Life Sciences, Transgene, Tasly, U.S. Department of Health and Human Services.